You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Abuse-Deterrent Formulations of Opioid Analgesics: Using Real-World Data for Clinical Decision-Making

  • Authors: Jody Green, PhD, FAACT; Charles Argoff, MD
  • CME / CE Released: 1/5/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 1/5/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for neurologists, anesthesiologists, primary care physicians, pharmacists, and other clinicians in a position to prescribe an opioid analgesic.

The goal of this activity is to increase knowledge of real-world data (RWD) for abuse-deterrent formulations (ADFs) of opioid analgesics and how such information can be used to guide treatment decisions in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for using RWD to study the effect of opioid analgesic ADFs
    • Clinical data derived from studies of RWD specific to the use of opioid analgesic ADFs


Faculty

  • Jody Green, PhD, FAACT

    Chief Scientific Officer
    Integrated Behavioral Health
    Inflexxion
    Irvine, California

    Disclosures

    Disclosure: Jody Green, PhD, FAACT, has disclosed the following relevant financial relationships:
    Grants for clinical research from: Collegium Pharmaceuticals, Inc.; Inflexxion
    Other: Served as expert witness for Endo Health Solutions, Inc.; Endo Pharmaceuticals, Inc.; Indivior Inc.; Indivior UK Limited

  • Charles Argoff, MD

    Professor of Neurology
    Albany Medical College
    Vice Chair, Department of Neurology
    Director, Comprehensive Pain Center
    Albany Medical Center
    Albany, New York

    Disclosures

    Disclosure: Charles Argoff, MD, has disclosed the following relevant financial relationships:
    Grants for clinical research from: AbbVie, Inc.; Amgen, Inc.; Lilly; Lundbeck, Inc.; Teva
    Advisor or consultant for: PharmaAmgen, Inc.; BioDelivery Sciences International; Collegium Pharmaceutical; Neumentum; Nevro; RedHill Biopharma, Ltd.; Tremeau Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated; XGene Pharma
    Speaker or member of speakers bureau for: AbbVie, Inc.; Amgen, Inc.; Biohaven Pharmaceuticals; Grünenthal Group; Lilly; Lundbeck, Inc.; RedHill Biopharma, Ltd.; Teva
    Royalties or patent beneficiary: Elsevier
    Stocks, stock options, or bonds from: Pfizer

Editors

  • Kathy Merlo

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Kathy Merlo has disclosed no relevant financial relationships.

  • Christin Melton, ELS

    Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Christin Melton, ELS, has disclosed no relevant financial relationships.

CE Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

All other faculty, planners and non-faculty contributors involved in the planning, development, editing, and review of the content have no relevant financial relationships with ineligible companies.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Mitigation 

All of the relevant financial relationships listed for these individuals have been mitigated. 


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-21-580-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Abuse-Deterrent Formulations of Opioid Analgesics: Using Real-World Data for Clinical Decision-Making

Authors: Jody Green, PhD, FAACT; Charles Argoff, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 1/5/2022

Valid for credit through: 1/5/2023, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to increase knowledge of real-world data (RWD) for abuse-deterrent formulations (ADFs) of opioid analgesics and how such information can be used to guide treatment decisions in clinical practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print